Calcium channel antagonists in the treatment of hypertension

American Journal of Cardiovascular Drugs

Volumn 2, Issue 6, 2002, Pages 415-431

  Weber, Michael A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PLACEBO; RAMIPRIL; VERAPAMIL;

ANGINA PECTORIS; BLEEDING; BLOOD PRESSURE REGULATION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DATA ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFECT; DRUG FORMULATION; DRUG TOLERABILITY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MONOTHERAPY; MORTALITY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STROKE; SURVIVAL; UNITED STATES;

CALCIUM CHANNEL BLOCKERS; DIABETES COMPLICATIONS; ENDPOINT DETERMINATION; HUMANS; HYPERTENSION; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036953069     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202060-00006     Document Type: Review

References (76)

1. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States. JAMA 1997; 278: 1747-8
2. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease: part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335 (8692): 765-74
3. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-66
4. Guidelines Subcommittee. 1999 World Health Organization: International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
5. Hansson L, Zanchetti A, Carruthers SC, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118): 1755-62
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
7. Klahr S, Levy AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease: modification of diet in renal disease study group. N Engl J Med 1994; 330: 877-84
8. Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey 1988-1991. Hypertension 1995; 25: 305-13
9. Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 272: 620-5
10. Kolata G. Heart attacks may have tie to drug type. New York Times 1995 Mar 11, 1
11. Group Health Cooperative of Puget Sound. Drug formulary. Hudson (OH): Lexi-Comp Inc, 1995
12. Jick H, Derby I, Gurewich V, et al. The risk of myocardial infarction in persons with uncomplicated hypertension. Pharmacotherapy 1996; 16: 321-6
13. Ruddy MC. The INSIGHT and NORDIL Trials. Are calcium antagonists equivalent to established drug therapies for cardiovascular protein? Curr Hypertens Rep 2001; 3: 289-96
14. Landmark K, Reikvam A, Abdelnoor M, et al. Acute myocardial infarction mortality related to use of calcium antagonists before admission to hospital. Cardiovasc Drugs Ther 1998; 12: 183-7
15. Alderman MH, Cohen H, Roque R, et al. Effect of long-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-8
16. Klungel OH, Heckbert SP, Longstreth WT, et al. Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med 2001; 161: 37-43
17. Pahor M, Guralnik J, Corti M, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1-7
18. Koenig W, Lowel H, Lewis M, et al. Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication: results of the Augsburg Myocardial Infarction follow-up Study 1985 to 1993. Eur Heart J 1996; 17: 199-206
19. Braun S, Boyko V, Behar S, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11 575 patients. J Am Coll Cardiol 1996; 28: 7-11
20. Abascal VM, Larson MG, Evans JC, et al. Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart study. Arch Intern Med 1998; 158: 1882-6
21. Michels KB, Rosner BA, Manson JE, et al. Prospective study of calcium channel blocker use cardiovascular disease and total mortality among hypertensive women: the Nurses' Health Study. Circulation 1998; 97: 1540-8
22. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80: 1453-8
23. Ruzicka M, Leenen FH. Relevance of 24 h blood pressure profile and sympathetic activity for outcome on short versus long-acting 1, 4 dihydropyridines. Am J Hypertens 1996; 9: 86-94
24. Grossman E, Messerli EH, Grodzicki T, et al. Should a moratorium be placed on nifedipine capsules in hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1328-31
25. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium channel antagonists. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1995: 2815-25
26. Leenen FHH. Dihydropyridine calcium antagonists and sympathetic activity: relevance to cardiovascular morbidity and mortality. In: Epstein M, editor. Calcium antagonists in clinical medicine. Philadelphia, (PA): Hanley and Belfus, 1998: 527-52
27. Huang BS, Leenen FHH. Sympathoinhibitory effects of central nifedipine in spontaneously hypertensive rats on high versus regular sodium intake. Hypertension 1999; 33: 32-5
28. Murzenok PP, Huang BS, Leenen FHH. Sympatho-inhibition by central and peripheral infusion of nifedipine in spontaneously hypertensive rats. Hypertension 2000; 35: 631-6
29. Leenen FHH, Ruzicka M, Huang BS. Central sympathoinhibitory effects of calcium channel blockers. Curr Hypertens Rep 2001; 3: 314-21
30. Lichtenberg G, Blankestijn PJ, Oey L, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8
31. Amery A, Birkenhager W, Bulpitt CJ, et al. SYST-EUR. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging Clin Exp Res 1991; 3: 287-302
32. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [published erratum appears in Lancet 1997; 350: 1639). Lancet 1997; 350: 757-4
33. Staessen JA, Thijs L, Birkenhager WH, et al., on behalf of the SYST-EUR Investigators. Update on the Systolic Hypertension in Europe (SYST-EUR) trial. Hypertension 1999; 33: 1476-7
34. Staessen JA, Thijs L, Fagard RH, et al., for the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998; 32: 404-9
35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189-98
36. Forette F, Seux ML, Staessen JA, et al., on behalf of the SYST-EUR Investigators. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (SYST-EUR) trial. Lancet 1998; 352: 1347-51
37. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64
38. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72
39. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Press 1993; 4: 312-21
40. Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65
41. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-98
42. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285 (21): 2719-26
43. Lewis EJ, Hunsicker G, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-9
44. Brenner BM, Cooper ME, DeZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
45. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52
46. Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 2000; 343: 1969
47. Sica D. Lessons learned from prematurely terminated clinical trials. Curr Hypertens Rep 2001; 3: 360-6
48. Tatti P, Guarisco R, De Mauro P, et al. Reduced risk of major cardiac events with the association of two antihypertensive therapies in non-insulin-dependent diabetic population [abstract]. Diabetes 1996; 45: A198
49. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-602
50. Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension in the Elderly Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92
51. Tuomilehto J, Rastenyte D, Birkenhager WH, et al., for the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84
52. Staessen JA, Thijs L, Fagard RH, et al., for the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998; 32: 404-9
53. Staessen JA. Clinical trials in older patients with systolic hypertension. In: Kaplan NM, editor. Hypertension therapy annual 2000. London: Martin Dunitz, 2000: 93-120
54. Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000 Jan 24; 160 (2): 211-20
55. Cutler JA. Calcium-channel blockers for hypertension: uncertainty continues. N Engl J Med 1998; 338: 679-81
56. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62
57. BP Trialists, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressuring-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955-64
58. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000; 356: 1949-54
59. Opie LH. Calcium channel blockers (CCBs) in hypertension: reappraisal after new trials and major meta-analyses. Am J Hypertens. 2001 Oct; 14 (10): 1074-81
60. Borhani N, Mercuri M, Borhani P, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS): a randomized controlled trial. JAMA 1996; 276: 785-91
61. Casiglia E, Spolaore P, Mazza A, et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study of the Elderly (CASTEL). Jpn Heart J 1994; 35: 589-600
62. Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-5
63. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-9
64. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-7
65. Connor J, Sawczuk IS, Benson MC, et al. Calcium channel antagonists delay regression of androgen dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 119-30
66. Ray SD, Kamendulis LM, Gurule MW, et al. Ca2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993; 7: 453-63
67. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341: 1251-4
68. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1995; 18: 137-53
69. Dargie HJ. Calcium channel blockers and the clinician. Lancet 1996; 348: 488-9
70. Epstein M. Safety of calcium antagonists as antihypertensive agents: an update. Am J Hypertens 1996; 9: 110-21
71. Packer M, O'Connor CM, Ghali JK, et al., for the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14
72. Gong L, Zhan W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14: 1237-45
73. Dahlof B. Anglo-Scandinavian cardiac outcomes trial. Am J Hypertens 1998; 11: 9A-10A
74. Black HR, Elliott WJ, Neaton JD, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Control Clin Trials 1998; 19: 370-90
75. Herbette LG, Vecchiarelli M, Sartani A, et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance: updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998; 7 Suppl. 2: 10-7
76. Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res Clin Exp 2000; 61: 850-62